Motilal Oswal

Aventis Pharma

STOCK INFO. BSE Sensex: 13,607	BLOOMBERG HOEC IN	17 Apı	ril 2007									Buy
S&P CNX: 3,985	REUTERS CODE AVPH.BO	Previo	us Recomm	endatio	n: Buy							<u>Rs1,200</u>
Equity Shares (m)	23.0	YEAR	NET SALES	РАТ	EPS	EPS	P/E	P/BV	ROE	ROCE	EV/	EV/
52-Week Range	2,125/1,160	END	(RSM)	(RSM)	(RS)	GROWTH (%)	(X)	(X)	(%)	(%)	SALES	EBITDA
1,6,12 Rel. Perf. (%)	-11/-28/-55	12/06A	8,840	1,693	73.5	5.7	16.3	4.7	28.6	41.5	2.6	10.6
M.Cap. (Rs b)	27.6	12/07E	9,661	1,866	81.0	10.2	14.8	3.9	26.2	39.2	2.3	9.1
M.Cap. (US\$ b)	0.7	12/08E	10,750	2,098	91.1	12.4	13.2	3.2	24.7	37.0	1.9	7.6

Aventis Pharma's 1QCY07 results were lower than our estimates with sales growth of 6.2% and PAT growth of 17.3%. Key highlights:

- Net sales grew by 6.2%, driven by 11% domestic sales growth to Rs1.7b. However export sales de-grew by 10% to Rs423m, restricting sales growth.
- ∠ EBITDA margins declined by 130bp to 23.2% mainly due to adverse product-mix and higher staff cost which increased by 17.3% YoY.
- ∠ However, higher other income (up by 108% to Rs200m), including a one-time write-back of Rs50m related to excess provisions in the past, boosted PAT to Rs433m, a growth of 17.3%.
- \swarrow We are downgrading our CY07E and CY08E EPS estimates by 3.5% and 5% respectively, to factor in lower than expected export sales. The company is yet to give any clarity on the erratic growth in export revenues. Subsequently, we have downgraded our price target by 13% to Rs1,800 (~20x CY08E EPS).

We believe that Aventis will be one of the key beneficiaries of the patent regime in the long-term. The parent has a strong R&D pipeline and plans to file 40 NDAs by CY10E. We continue to remain positive on Aventis' long-term prospects. Despite the cut in our earnings estimates, we believe that, at 14.8x CY07E and 13.2x CY08E earnings, valuations are reasonable. Maintain **Buy**.

Y/E DECEMBER		CYO	6			CYO	7		CY06	CY07E
	1Q	2 Q	3 Q	4 Q	1Q	2QE	3QE	4QE		
Net Sales	2,005	2,228	2,431	2,176	2,129	2,476	2,681	2,376	8,840	9,66 1
YoY Change (%)	16.2	4.4	8.8	11.2	6.2	11.1	10.3	9.2	9.4	9.3
Total Expenditure	1,513	1,609	1,744	1,749	1,635	1,815	1,957	1,790	6,633	7,196
EBITDA	492	619	687	427	494	661	724	586	2,207	2,465
Margins (%)	24.5	27.8	28.3	19.6	23.2	26.7	27.0	24.7	25.0	25.5
Depreciation	43	42	43	51	45	46	47	57	179	195
Interest	0	1	0	1	0	0	0	0	2	(
Other Income	96	90	156	111	200	118	146	98	471	561
PBT before EO Items	545	666	800	486	649	733	824	627	2,497	2,832
Extra-Ord Expense	0	0	0	0	0	0	0	0	0	(
PBT after EO Items	545	666	800	486	649	733	824	627	2,497	2,832
Тах	176	227	262	139	216	250	281	219	804	966
Effective tax Rate (%)	32.3	34.1	32.8	28.6	33.3	34.1	34.1	35.0	32.2	34.1
Reported PAT	369	439	538	347	433	483	543	407	1,693	1,866
Adj PAT	369	439	538	347	433	483	543	407	1,693	1,866
YoY Change (%)	56.4	28.4	8.2	-7.7	17.3	10.0	0.9	17.4	16.7	10.2
Margins (%)	18.4	19.7	22.1	15.9	20.3	19.5	20.2	17.2	19.2	19.3


Nimish Desai (Nimishdesai@MotilalOswal.com); Tel: +91 22 39825406/Jinesh K Gandhi (Jinesh@MotilalOswal.com); Tel +91 22 39825416

Decline in exports restricts sales growth

Aventis's net sales for 1QCY07 grew by 6.2% to Rs2.1b, primarily driven by 11% YoY growth in domestic sales to Rs1.7b. However, exports business de-grew by 10% to Rs423m, the lowest export sales since 1QCY04.


	-	•	nv/Motila		• •••
Net Sales	2,129	2,005	6.2	2,176	-2.2
% of Sales	19.9	23.4		29.2	
Exports	423	470	-10.0	636	-33.5
% of Sales	80.1	76.6		70.8	
Net Domestic Sales	1,706	1,535	11.1	1,540	10.8
	CY07	CY06	(%)	CY06	(%)
	1Q	1Q	YOY	4Q	QOQ

irce: Company/Motilal Oswal Securities




Source: Company/Motilal Oswal Securities

Domestic business continues to do well, despite high base of 1QCY06 which witnessed recovery in sales post-VAT implementation.



EBITDA margins decline; higher other income boosts PAT

EBITDA margins declined by 130bp to 23.2% mainly due to adverse product-mix and higher staff cost which increased by 17.3% YoY. However, higher other income (up by 108% to Rs200m), including a one-time write-back of Rs50m related to excess provisions in the past, boosted PAT to Rs433m, a growth of 17.3%.



Source: Company/Motilal Oswal Securities

Withdrawal of Cox-II inhibitors may benefit Aventis India

We believe that the withdrawal of Rofecoxib and Valdecoxib (cox-II inhibitors) from the global and Indian markets due to adverse side effects may have a positive impact on the sales of older (and proven) painkillers like APL's Combiflam. Historically, Combiflam has grown in single digits. Higher growth for Combiflam can have a positive impact on EBITDA margins since it commands a very high brandequity. Products such as Combiflam are cash cows, and the company does not spend on promotion for such products.

Aventis-Sanofi – Global merger

Sanofi has a 100% subsidiary in India, which is engaged in the marketing of the parent's products, especially in the CVS and CNS segments. APL's management had indicated that if this arm were to be merged with APL, it would be earnings accretive. While APL has not indicated any figures, we believe that Sanofi India has a small business generating about Rs1b of revenues. On the positive side, there seems to be very little over-lap (except in the CVS segment) between APL's and Sanofi's product portfolios in the Indian market with the latter focusing on CVS and CNS segments. APL will draw strength from the combined R&D pipeline of the global parent, which has become the third largest player in the global pharmaceutical industry.

Sanofi (India) specializes in 4 main therapeutic groups, Thrombosis (major brands- Faxiparine, Tyklid and Plavix) Cardiovascular (Adenocor, Primacor) Neurlogy, (Valparin, Jume) and Internal Medicine (Ladogal Lactacyd, Fortagesic and Calcium Resonium).

New product launches may slow down

APL has been most aggressive in new launches amongst its peers and has launched most of the top products of the parent in India. Aventis launched Lantus (anti-diabetic) and Actonel (Osteoporosis) in the anti-diabetic and pain management segments in CY03. It has not launched any

PRODUCT	INDIA L	AUNCH	I POSSIBILITY OF
	LAUNCH	YEAR	LAUNCH IN INDIA
Lovenox/Clexane	Y		N.A.
Plavix/Iscover -	Y		N.A.
Sanofi Product			
Allegra	Y	1998	N.A.
Taxotere	Y		N.A.
Stilnox/Ambien/Myslee	Ν		No - Global launch in 1992.
- Sanofi Product			Old product
Eloxatin - Sanofi Product	Ν		Yes - Global launch in 1996
Delix/Tritace/Triatec	Y	1994	N.A.
Lantus	Y	2003	N.A.
Aprovel/Avapro/Karvea	Ν		Yes - Global launch in 1997
- Sanofi Product			But Indian companies have
			already launched this
			product
Copaxone	Ν		No - Product belongs to
			Teva
Amaryl	Y	1999	N.A.
Actonel	Y	2003	N.A.
Depakine - Sanofi Produc	et Y		N.A.
Nasacort - Sanofi	Status		
Product n	ot knowi	n	
Xatral - Sanofi Product	Ν		Unlikely - It is a 1988
			product

new products in CY04 and launched Apidra (anti-diabetic) in CY05. We believe that the parent's portfolio is very well mapped in the domestic entity, which leaves little scope of aggressive new launches going forward. The table below indicates the details on past launches as well as the status for potential new products.

Well placed to benefit from the patent regime

Over the longer term, Aventis is well placed to benefit from the introduction of product patents, given its strengths in marketing, a supportive parent and a healthy product pipeline (of NCEs) following the formation of Sanofi-Aventis. Aventis' history of launching patented products in India, a well mapped portfolio vis-à-vis the parent and ability to build them into big brands make it one of the biggest potential beneficiaries of the product patent regime in India.

We believe that the patent regime will bring-in significant benefits for Aventis, albeit in the long-term. We expect launch of patented products from the parent's portfolio by 2008/09. The company is yet to give visibility on launch of patented products in India.

To benefit from the parent's R&D pipeline

Sanofi-Aventis currently has 125 projects in research and development, including about 38 in pre-clinical development and 58 in late stage (Phase II & III) development. It is planning to file about 31 NDAs and 9 vaccines with the regulatory authorities by CY10E. The table below gives details on the parent's R&D pipeline:

NO. OF	F	PRE-		PI	HASE		TOTAL
DRUGS	CLINI	CAL	I.	IIA	IIB	Ш	
Cardiovascular		2	5	1	4	1	13
Thrombosis		3	1	0	3	2	9
Central Nervous Sys	stem	8	8	1	4	6	27
Oncology		7	4	1	0	6	18
Metabolic Disorders		2	1	2	4	0	9
Internal Medicine		9	5	5	4	2	25
Vaccines		7	5	2	2	8	24
Total		38	29	12	21	25	125

Although, clarity on launch of these drugs will emerge only over a period of time, we believe that some of these products could be relevant for the Indian markets and are likely to be launched in India with a time-lag. However, uncertainty still remains on whether these products will be launched through the listed subsidiary or the 100% subsidiary.

Revising estimates downwards

We are revising our earnings estimates for CY07E and CY08E downwards, by 3.5% and 5% respectively. Revision in estimates is primarily to factor in for lower than expected export sales. Our estimates now factor in for growth in export sales of 8% (v/s 15% earlier) in CY07E. Also, we have marginally increased our assumptions for domestic sales growth to 10% (v/s 9% earlier). Domestic sales growth of 10% in CY07E is on high base of CY06, where sales were boosted in pain management segment due to outbreak of Chikungunya.

REVISED FOR	ECAST (RS I	VI)				
		CY07			CY08	
	REV	OLD	CHG (%)	REV	OLD	CHG (%)
Net Sales	9,661	9,975	-3.1	10,750	11,120	-3.3
Net Profit	1,866	1,935	-3.5	2,098	2,214	-5.2
EPS (Rs)	81.0	84.0	-3.5	91.1	96.1	-5.2
		Sourc	e: Compa	ny/Motilal	Oswal	Securities

We believe that the biggest risk to our positive stance on Aventis could be the implementation of the new pharmaceutical policy in the current form. The new policy proposes to significantly increase the span of control by bringing in additional 354 drugs under price control. This could severely impact the profitability of APL's domestic

New drug policy still remains uncertain

business. Industry has taken strong objection to the proposed policy and we believe that the policy is unlikely to be implemented in the current form. Given the strong opposition from the industry, the government has formed a Group on Ministers (GoM), which would give final recommendations to the government regarding the new pharmaceutical policy. However, the uncertainty related to this will remain till the government finally notifies the new pharmaceutical policy.

Valuation and outlook

APL has an impeccable track record of brand building in the domestic market with its strategic brands recording double digit growth consistently. In the long-term, focus on growing strategic brands and strong support from the parent will augur well for the company. We believe that it is very well positioned to take advantage of the patent regime in the long-term. It is in the process of integrating Sanofi's domestic operation with itself (post the global merger). We believe that there is very little over-lap between APL and Sanofi's portfolio in India.

We believe that Aventis will be one of the key beneficiaries of the patent regime in the long-term. The parent has a strong R&D pipeline and plans to file 40 NDAs (incl. vaccines) by CY10E. We continue to remain positive on Aventis' long-term prospects. Despite the cut in our earnings estimates, we believe that, at 14.8x CY07E and 13.2x CY08E earnings, valuations are reasonable. We have also revised our target price downwards by 13% to Rs1,800 to take into account the reduction in earnings estimates as well as low visibility of future (management has not interacted with investors for almost 2 years). Maintain **Buy**.

Aventis Pharma: an investment profile

Company description

Aventis (50% subsidiary of Aventis SA) is the second largest MNC and among the top 10 formulations players in India. The company has built a very strong franchise in chronic therapy areas like anti-diabetes, oncology and CVS, in the process realigning its domestic portfolio with that of its parent. Aventis is currently undergoing transformation, with the parent being taken over by Sanofi Synthelabo worldwide.

Key investment arguments

- Significant improvement in product mix, with enhanced focus on strategic products and rationalization of older products has put it back on the growth path.
- Aggressive cost cutting and improved efficiencies to add to revenue growth and boost operating performance.
- Strong parental commitment and excellent brand equity among doctors make it the best placed MNC to gain from the IPR regime. Parent plans 40 NDA filings by CY10.

COMPARATIVE VALUATIONS

		AVENTIS	GSK	PFIZER
P/E (x)	CY07E	14.8	24.2	23.1
	CY08E	13.2	20.9	19.6
P/BV (x)	CY07E	3.9	6.9	3.7
	CY08E	3.2	5.7	3.4
EV/Sales (x)	CY07E	2.3	5.0	3.1
	CY08E	1.9	4.3	2.7
EV/EBITDA (x)	CY07E	9.1	15.9	13.4
	CY08E	7.6	13.3	11.1

SHAREHOLDING PATTERN (%)

	MAR.07	DEC.06	MAR.06
	00.4	00.4	00.4
Promoter	60.4	60.4	60.4
Domestic Inst	18.9	19.6	15.6
Foreign	9.3	9.5	13.9
Others	11.4	10.6	10.2

Key investment risks

- Sanofi's acquisition of Aventis SA could hamper Indian operations if new parent is not committed.
- ✓ Exports have been de-growing for the last four quarters.
- The proposed new drug policy could adversely impact APL.

Valuation and view

- Valuations of 14.8x CY07E and 13.2x CY08E earnings do not fully factor-in the future prospects, excellent return ratios and free cash on books (around Rs186/ share in CY06E).
- ∠ Maintain **Buy** with a revised target price of Rs1,800.

Sector view

- Indian Pharma market expected to witness steady growth, on the back of gradual increase in the low penetration levels – companies with strong brands and marketing muscle to benefit the most.
- IPR regime unlikely to lead to any major change in the near term; MNCs and large Indian players to benefit over the longer term.
- Among MNCs, we are bullish on companies where risk of conflict with 100% subsidiaries is limited.

EPS: MOST FORECAST VS CONSENSUS (RS)

	MOST	CONSENSUS	VARIATION
	FORECAST	FORECAST	(%)
CY07	81.0	87.0	-6.9
CY08	91.1	96.7	-5.8

TARGET PRICE	AND RECOMMENDATION		
CURRENT	TARGET	UPSIDE	RECO.
PRICE (RS)	PRICE (RS)	(%)	
1,200	1,800	50.0	Buy

STOCK PERFORMANCE (1 YEAR)



MOTILAL OSWAL

INCOME STATEMENT				(Rs	Million)
Y/E DECEMBER	2004	2005	2006	2007E	2008E
Exports	2,041	2,287	2,258	2,439	2,804
Net Domestic Sales	5,266	5,732	6,582	7,223	7,948
Net Sales	7,307	8,019	8,840	9,661	10,750
Change (%)	12.0	9.8	10.2	9.3	11.3
Total Expenditure	5,162	5,741	6,633	7,196	8,004
EBITDA	2,145	2,278	2,207	2,465	2,746
Change (%)	53.5	6.2	-3.1	11.7	11.4
Margin (%)	29.4	28.4	25.0	25.5	25.5
Depreciation	168	172	179	195	20
Int. and Finance Charges	1	0	2	0	(
Other Income - Rec.	218	295	471	561	643
PBT & EO Items	2,194	2,401	2,497	2,832	3,184
Change (%)	58.9	9.4	4.0	13.4	12.4
Extra Ordinary Income/(Exp)	68	0	0	0	(
PBT after EO Items	2,262	2,401	2,497	2,832	3,184
Тах	777	799	804	966	1,08
Tax Rate (%)	34.4	33.3	32.2	34.1	34.1
Reported PAT	1,485	1,602	1,693	1,866	2,098
PAT Adj for EO Items	1,440	1,602	1,693	1,866	2,098
Change (%)	53.5	11.2	5.7	10.2	12.4
Margin (%)	19.7	20.0	19.2	19.3	19.5

BALANCE SHEET				(Rs	Million)
Y/E DECEMBER	2004	2005	2006	2007E	2008E
Equity Share Capital	230	230	230	230	230
Reserves	3,810	4,838	5,691	6,901	8,276
Revaluation Reserves	178	170	161	153	145
Net Worth	4,218	5,238	6,082	7,284	8,651
Loans	0	0	0	0	0
Deferred Tax Liabilities	-5	-57	-57	-57	-57
Capital Employed	4,213	5,181	6,025	7,227	8,594
Gross Block	2,742	2,794	2,924	3,074	3,233
Less: Accum. Deprn.	1,225	1,389	1,569	1,772	1,985
Net Fixed Assets	1,5 17	1,405	1,356	1,303	1,248
Capital WIP	28	13	25	25	25
Investments	53	53	53	53	53
Curr. Assets	4,111	5,419	6,240	7,398	8,980
Inventory	1,016	1,363	853	932	953
Account Receivables	918	510	898	979	1,089
Cash and Bank Balance	1,673	2,944	4,265	5,261	6,707
Others	504	601	223	226	231
Curr. Liability & Prov.	1,496	1,710	1,648	1,552	1,711
Account Payables	665	846	808	896	989
Provisions	831	864	840	656	722
Net Current Assets	2,616	3,709	4,592	5,846	7,268
Appl. of Funds	4,213	5,181	6,025	7,227	8,594

RATIOS					
Y/E DECEMBER	2004	2005	2006	2007E	2008E
Basic (Rs)					
EPS	62.5	69.6	73.5	81.0	91.1
Cash EPS	69.8	77.0	81.3	89.5	100.0
BV/Share	175.4	220.1	257.1	309.6	369.4
DPS	16.0	16.0	32.0	25.0	27.5
Payout (%)	28.1	26.4	49.6	35.2	34.4
Valuation (x)					
P/E		17.2	16.3	14.8	13.2
Cash P/E		15.6	14.8	13.4	12.0
P/BV		5.5	4.7	3.9	3.2
EV/Sales		3.1	2.6	2.3	1.9
EV/EBITDA		10.8	10.6	9.1	7.6
Dividend Yield (%)		1.3	2.7	2.1	2.3
Return Ratios (%)					
RoE	35.6	31.6	28.6	26.2	24.7
RoCE	52.1	46.4	41.5	39.2	37.0
Working Capital Ratios					
Asset Turnover (x)	1.7	1.5	1.5	1.3	1.3
Debtor (Days)	46	23	37	37	37
Inventory (Days)	51	62	35	35	32
Working Capital (Days)	47	35	13	22	19
Leverage Ratio					
Current Ratio	2.7	3.2	3.8	4.8	5.2
Debt/Equity	0.0	0.0	0.0	0.0	0.0
CASH FLOW STATEMENT				(Re	Million)
Y/E DECEMBER	2004	2005	2006	2007E	2008E
	2 145	2 278	2 207	2 465	2 746

Y/E DECEMBER	2004	2005	2006	2007E	2008E
OP/(Loss) before Tax	2,145	2,278	2,207	2,465	2,746
Interest/Dividends Recd.	218	295	471	561	643
Direct Taxes Paid	-772	-851	-804	-966	-1,086
(Inc)/Dec in WC	-560	177	438	-259	24
CF from Operations	1,032	1,900	2,312	1,802	2,326
EO Items	68	0	0	0	0
CF from Ope (EO items)	1, 100	1,900	2,312	1,802	2,326
(Inc)/Dec in FA	-73	-54	-150	-150	-158
(Pur)/Sale of Investments	0	0	0	0	0
CF from Investments	-73	-54	-149	-150	- 158
Issue of Shares	-54	-151	0	0	0
(Inc)/Dec in Debt	-152	0	0	0	0
Interest Paid	-1	0	-2	0	0
Dividend Paid	-417	-423	-840	-656	-722
CF from Fin. Activity	-625	-574	-842	-656	-722
Inc/Dec of Cash	402	1,271	1,321	996	1,446
Add: Beginning Balance	1,271	1,673	2,944	4,265	5,261
Closing Balance	1,673	2,944	4,265	5,261	6,707

NOTES



For more copies or other information, contact **Institutional:** Navin Agarwal. **Retail:** Manish Shah Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: inquire@motilaloswal.com **Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai 400 021**

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (*hereinafter referred as MOSt*) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form.

The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOSt or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MOSt and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Disclosure of Interest Statement A	ventis Pharma
1. Analyst ownership of the stock	No
Group/Directors ownership of the stock	Yes
3. Broking relationship with company covered	No
4. Investment Banking relationship with company covered	No

This information is subject to change without any prior notice. MOSt reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOSt is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.